Differential Effects of the G118R, H51Y, and E138K Resistance Substitutions in Different Subtypes of HIV Integrase

Dolutegravir (DTG) is the latest antiretroviral (ARV) approved for the treatment of human immunodeficiency virus (HIV) infection. The G118R substitution, previously identified with MK-2048 and raltegravir, may represent the initial substitution in a dolutegravir resistance pathway. We have found tha...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:J Virol
Autors principals: Quashie, Peter K., Oliviera, Maureen, Veres, Tamar, Osman, Nathan, Han, Ying-Shan, Hassounah, Said, Lie, Yolanda, Huang, Wei, Mesplède, Thibault, Wainberg, Mark A.
Format: Artigo
Idioma:Inglês
Publicat: American Society for Microbiology 2014
Matèries:
Vaccines and Antiviral Agents
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC4337543/
https://ncbi.nlm.nih.gov/pubmed/25552724
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1128/JVI.03353-14
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars